Studying and modulating schizophrenia-associated dysfunctions of oligodendrocytes with patient-specific cell systems. (December 2018)

• Record Type: Journal Article
• Authors: Raabe, Florian; Galinski, Sabrina; Papiol, Sergi; Falkai, Peter; Schmitt, Andrea; Rossner, Moritz
• Is Part Of: NPJ schizophrenia. Volume 4(2018)
• Page Start: 1
• Page End: 11
• Publication Date: 2018-12
• Subjects: Schizophrenia -- Periodicals; 616.898
• DOI: 10.1038/s41537-018-0066-4
• Languages: English
• ISSNs: 2334-265X

Abstract

Abstract Postmortem studies in patients with schizophrenia (SCZ) have revealed deficits in myelination, abnormalities in myelin gene expression and altered numbers of oligodendrocytes in the brain. However, gaining mechanistic insight into oligodendrocyte (OL) dysfunction and its contribution to SCZ has been challenging because of technical hurdles. The advent of individual patient-derived human-induced pluripotent stem cells (hiPSCs), combined with the generation of in principle any neuronal and glial cell type, including OLs and oligodendrocyte precursor cells (OPCs), holds great potential for understanding the molecular basis of the aetiopathogenesis of genetically complex psychiatric diseases such as SCZ and could pave the way towards personalized medicine. The development of neuronal and glial co-culture systems now appears to enable the in vitro study of SCZ-relevant neurobiological endophenotypes, including OL dysfunction and myelination, with unprecedented construct validity. Nonetheless, the meaningful stratification of patients before the subsequent functional analyses of patient-derived cell systems still represents an important bottleneck. Here, to improve the predictive power of ex vivo disease modelling we propose using hiPSC technology to focus on representatives of patient subgroups stratified for genomic and/or phenomic features and neurobiological cell systems. Therefore, this review will outline the evidence for the involvement of OPCs/OLs in SCZ in the context of their proposed functions, including myelination and axon support, the implications for hiPSC-based cellular disease modelling and potential strategies for patient selection.